Clinical Trial Update: Effects of Arzoxifene on Bone Mass and the Uterus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating arzoxifene's effects on bone mass and uterine outcomes in postmenopausal bone loss has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Arzoxifene (arzoxifene)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Postmenopausal Bone Loss | Phase 3 | Status: COMPLETED